ArticleFrontiers in pharmacology2025
Case Report: Linezolid-associated toxic optic neuropathy in patients with pulmonary tuberculosis: case series and mini review.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Probable linezolid-associated bilateral toxic optic neuropathy after prolonged therapy: A case report.The Journal of international medical research · 2026Article
- Linezolid-Induced Optic Neuritis in Tuberculosis: A Systematic Review of Case Reports, Case Series, and Cohort Studies.Tuberculosis and respiratory diseases · 2026Article
- Protective Effect of Exogenous Adenosine Triphosphate Against Ocular Toxicity of Linezolid in Rats.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid is a useful second-line medication for the treatment of tuberculosis that is resistant to multiple drugs. However, long-term therapy can cause side effects, such as optic neuropathy. We describe three cases of progressive painless bilateral visual loss in patients taking long-term linezolid therapy for multidrug-resistant and extensively drug-resistant tuberculosis. We reviewed the literatures and identified 58 cases of linezolid optic neuropathy. Discontinuation of linezolid resulted in a marked improvement in vision, however it was not complete in all patients. Knowledge of visual monitoring of patients undergoing long-term linezolid therapy is important for physicians and ophthalmologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.